Cart

0

Stocks

“Bluebird’s stock falls 21% as it says it will focus on U.S. market for gene therapies, citing ‘European payers'”

“Shares of Bluebird Bio Inc. were down 21.6% in premarket trading on Monday after the company announced several setbacks to its business as part of its second-quarter earnings announcement. Bluebird plans to wind down its gene therapy operations in Europe,… Continue Reading…

Stocks

“Intellia Stock Could Surge 35-45% After Positive Gene Editing Data, Says Analyst”

“On Saturday, the company released interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder… While it is still early days, Issi calls the data… Continue Reading…